Principal Investigator
Carlos Singer
Enrollment Status
Open
Clinical Trial ID
Institutional Protocol #
20230418
Clinical Trial Summary
A Randomized, Double-blind, Placebo-controlled Multicenter Study to Assess the Efficacy and Safety of Lenrispodun as Adjunctive Therapy in the Treatment of Patients with Motor Fluctuations due to Parkinsons Disease
Phase
Phase II
Funding Agency/Sponsor
Industry
Disease
Movement Disorders